Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Delayed SARS-COV-2 leukoencephalopathy without Severe Hypoxia

To the Editor

A 35-year-old African American female with history of gastric bypass surgery and iron deficiency anemia had a positive nasopharyngeal swab for SARS-CoV-2 PCR in April 2020 in the setting of anosmia and ageusia. Per her sister’s report, she did not have confusion, dyspnea, or cough. She did not receive any treatment for COVID-19. Bloodwork in May 2020 demonstrated positive serum SARS-CoV-2 antibodies.

In early June 2020, she presented to an outside emergency department with six days of gait instability. Per documentation, her neurologic evaluation revealed symmetric distal neuropathy. MRI brain without contrast was read as “hemispheric white matter signal appears somewhat elevated…with sparing of juxtacortical regions…extend[ing] to anteromedial temporal lobes…less conspicuous in posterior fossa.” Vitamin and mineral levels were sent to evaluate her neuropathy; zinc, copper, and vitamins B1, B6 and B12, were normal, but vitamin E was low, so she was started on supplemental tocopherol. Additionally, due to her history of COVID-19, erythrocyte sedimentation rate (ESR) and D-dimer were checked; both were elevated [ESR was 105 mm/h (normal 0–22 mm/h) and D-dimer was 308 ng/mL (normal < 230 ng/mL)]. She was discharged from the emergency room with a plan for outpatient follow up with neurology.

Seven days later, she presented to a different emergency room due to persistent gait instability, decreased appetite and generalized weakness. Per documentation, she was drowsy and slow to respond. Per report, non-contrast head CT, urine toxicology, C-reactive protein, HIV screen, basic metabolic panel and complete blood cell count were within normal limits. Nasopharyngeal swab for SARS-COV-2 PCR was negative. On hospital day 2, she became more lethargic, so a lumbar puncture was performed; it demonstrated 1 WBC, 0 RBC, protein of 22 mg/dL, glucose 76 mg/dL, negative meningitis-encephalitis panel (E. coli, H. flu, Listeria, N. Meningitis, S. Agalactaia, S. Pneumo, CMV, Enterovirus, HSV1, HSV2, HHV6, VZV, and cryptoccocus), and negative culture. Transvaginal ultrasound did not reveal a teratoma. By hospital day 4, she was unarousable to noxious stimuli. MRI brain with and without contrast was repeated and, while it was severely motion degraded, it showed symmetric periventricular white matter FLAIR hyperintensities involving bilateral cerebral peduncles with mild diffusion restriction. Although she had been hemodynamically stable since admission and did not require supplemental oxygen, she was upgraded to the ICU for close monitoring. On hospital day 7, she was unable to clear her secretions and desaturated to 70%, prompting intubation. She had a CT chest which demonstrated “sequela of post-infectious chronic bronchiolitis.”

At this time, she was transferred to our tertiary hospital for further care. On initial examination, while on propofol, she was unarousable to noxious stimulation, had intact brainstem reflexes, extended her upper extremities, and triple flexed her lower extremities to deep naiibled pressure. Repeat MRI brain demonstrated extensive diffuse confluent periventricular, temporal, subcortical and midbrain hyperintensities overall mildly progressed since prior MRI (see Figs. 1 and 2) with mild patchy diffusion restriction, no contrast enhancement, and no evidence of microhemorrhages on SWI. MRI head showed normal vessels. MRI of the total spine did not show any evidence of cord pathology. Electroencephalogram demonstrated mild to moderate slowing with no epileptiform activity.

A second lumbar puncture was performed and demonstrated 2 WBC, 51 RBC, protein 19 mg/dL, glucose 70 mg/dL and negative: culture, meningitis-encephalitis panel (same as afore mentioned panel), JC virus, West Nile PCR, EBV PCR, HSV1/2 PCR, and oligoclonal bands. Myelin Basic Protein (MBP) was elevated at 8.4 μg/L (normal 2.0–4.0 μg/L). Autoimmune encephalitis panel was normal. Serum aquaporin-4 antibody and myelin oligodendrocyte glycoprotein antibody were negative. Both nasopharyngeal swab for SARS-CoV-2 PCR and serum SARS-CoV-2 IgG were negative twice. We were unable to send SARS-CoV-2 PCR or antibody in the cerebrospinal fluid. Additional tests to assess for a rheumatologic process including anti-nuclear antibodies, anti-AMA, anti-JO-1, anti-LKM, anti-phospholipid antibodies and IgG levels all returned within normal limits. Serum ceruloplasm, lyme serologies, and vitamin A were also within normal limits.

Based on these results, her condition was attributed to post-infectious acute disseminated encephalomyelitis (ADEM) related to her prior COVID-19 infection. She was treated with 1 mg/kg methylprednisolone for 5 days and 2 g/kg of intravenous immunoglobulin (IVIG) divided over 3 days. As she did not improve, we subsequently administered 5 days of plasma exchange (PLEX) therapy. Unfortunately, as of hospital day 48, she had not improved, and was transferred to a long term care facility.

There are many etiologies for white matter changes on an MRI brain including, but not limited to, ADEM, multiple sclerosis, inherited white matter diseases, lymphoma, progressive multifocal leukoencephalopathy, cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy, toxic metabolic changes, vasculitis, sarcoidosis, age, radiation, and lyme disease [1]. Recently, there have been multiple reports of leukoencephalopathy in patients with COVID-19, all of whom were intubated for acute respiratory failure due to COVID-19 [2–6]. Since our patient did not have neuroimaging prior to June 2020, we cannot be certain that her white matter changes developed after onset of COVID-19. She did not have neurologic complaints until after she had COVID-19, and our extensive workup did not reveal another etiology for these changes, so we believe they are related to COVID-19.

A number of mechanisms have been proposed to explain leukoencephalopathy in the setting of acute COVID-19 including endothelitis with thrombotic microangiopathy, cytokine release syndrome, hypoxia, toxic or metabolic changes, sepsis, posterior reversible leukoencephalopathy and demyelination [2–6]. However, many of these mechanisms could not account for our patient’s leukoencephalopathy as she did not have severe COVID-19 and there was a lengthy delay between her initial symptoms of COVID-19 and the onset of her neurologic symptoms. While she did not complain of respiratory symptoms when she was diagnosed with COVID-19, it is worth noting that we cannot completely eliminate the possibility that she had mild hypoxia at this time, as some patients with COVID-19 have “silent hypoxia” without dyspnea [7]. Although SARS-CoV-2 has the potential to be neurotropic, white matter changes have not been attributed to direct invasion of the central nervous system [2–6,8]. In fact, the neuropathology from a patient who died two weeks after development of multiorgan failure due to COVID-19 demonstrated hemorrhagic white matter changes surrounded by macrophages and axonal injury similar to changes seen in patients with ADEM [9,10]. Accordingly, as our workup did not identify another etiology for her white matter changes, we concluded that our patient’s diffuse leukoencephalopathy was due to delayed demyelination from ADEM following infection with COVID-19. Of note, it is unclear if it is significant that she initially had antibodies to SARS-CoV-2 a month prior to presentation then did not have them when she was admitted; it has been reported that patients with COVID-19 can have diminished antibody levels over time, particularly when symptoms were mild [11].

Although prognosis of ADEM is generally favorable, it can be fatal [12]. Based on this report and others in the literature, leukoencephalopathy due to COVID-19 appears to be a harbinger of poor outcome [2–6]. However, we are unsure if she would have had a better outcome if steroids, IVIG, and/or PLEX were administered earlier, when her white matter lesions were first identified and she only had gait instability.

Larger studies are needed to understand the frequency of both acute and delayed leukoencephalopathy in patients with COVID-19, their histopathology, ideal treatment and outcome.

Funding
None.

Disclosures
All authors report no disclosures.

References
[1] S. Kanekar, P. Devgun, A pattern approach to focal white matter hyperintensities on magnetic resonance imaging, Radiol. Clin. N. Am. 52 (2014) 241–261.
[2] A. Radmanesh, A. Derman, K. Ishida, COVID-19-associated delayed posthypoxic necrotizing leukoencephalopathy, J. Neurol. Sci. 415 (2020) 116945.
[3] A. Radmanesh, A. Derman, Y.W. Lui, E. Raz, J.P. Loh, M. Hagiwara, et al., COVID-19-associated diffuse leukoencephalopathy and microhemorrhages, Radiology. (2020) 202040.
[4] L. Dixon, J. Varley, A. Gontsarov, D. Mallon, F. Tona, D. Muir, et al., COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia, Neurol. Neuroimmunol. Neuroinflamm. 7 (2020).
[5] J.R. Sachs, K.W. Gibbs, D.E. Swor, A.P. Sweeney, D.W. Williams, J.H. Bourette, et al., COVID-19-associated Leukoencephalopathy, Radiology (2020) 201755.
[6] M. Lang, K. Buch, M.D. Li, W.A. Mehan Jr., A.L. Lang, T.M. Leslie-Mazwi, et al., Leukoencephalopathy associated with severe COVID-19 infection: sequela of hypoxemia? AJNR Am. J. Neuroradiol. (2020).
[7] M.J. Tobin, F. Laghi, A. Jubran, Why COVID-19 silent hypoxemia is baffling to physicians, Am. J. Respir. Crit. Care Med. 202 (2020) 356–360.
[8] Y. Yachou, A. El Idrissi, V. Belapazov, Ait Benali S. Neuroinvasion, Neurotropic, and symptoms were mild [11].

Although prognosis of ADEM is generally favorable, it can be fatal [12]. Based on this report and others in the literature, leukoencephalopathy due to COVID-19 appears to be a harbinger of poor outcome [2–6]. However, we are unsure if she would have had a better outcome if steroids, IVIG, and/or PLEX were administered earlier, when her white matter lesions were first identified and she only had gait instability.

Larger studies are needed to understand the frequency of both acute and delayed leukoencephalopathy in patients with COVID-19, their histopathology, ideal treatment and outcome.

Funding
None.

Disclosures
All authors report no disclosures.

References
[1] S. Kanekar, P. Devgun, A pattern approach to focal white matter hyperintensities on magnetic resonance imaging, Radiol. Clin. N. Am. 52 (2014) 241–261.
[2] A. Radmanesh, A. Derman, K. Ishida, COVID-19-associated delayed posthypoxic necrotizing leukoencephalopathy, J. Neurol. Sci. 415 (2020) 116945.
[3] A. Radmanesh, A. Derman, Y.W. Lui, E. Raz, J.P. Loh, M. Hagiwara, et al., COVID-19-associated diffuse leukoencephalopathy and microhemorrhages, Radiology. (2020) 202040.
[4] L. Dixon, J. Varley, A. Gontsarov, D. Mallon, F. Tona, D. Muir, et al., COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia, Neurol. Neuroimmunol. Neuroinflamm. 7 (2020).
[5] J.R. Sachs, K.W. Gibbs, D.E. Swor, A.P. Sweeney, D.W. Williams, J.H. Bourette, et al., COVID-19-associated Leukoencephalopathy, Radiology (2020) 201755.
[6] M. Lang, K. Buch, M.D. Li, W.A. Mehan Jr., A.L. Lang, T.M. Leslie-Mazwi, et al., Leukoencephalopathy associated with severe COVID-19 infection: sequela of hypoxemia? AJNR Am. J. Neuroradiol. (2020).
[7] M.J. Tobin, F. Laghi, A. Jubran, Why COVID-19 silent hypoxemia is baffling to physicians, Am. J. Respir. Crit. Care Med. 202 (2020) 356–360.
[8] Y. Yachou, A. El Idrissi, V. Belapazov, Ait Benali S. Neuroinvasion, Neurotropic, and
neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients, Neurol. Sci. (2020) 1–13.

[9] R.R. Reichard, K.B. Kashani, N.A. Boire, E. Constantopoulos, Y. Guo, C.F. Lucchinetti, Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology, Acta Neuropathol. 140 (2020) 1–6.

[10] O.S. Abdelaziz, Z. Waffa, Neuropathogenic human coronaviruses: a review, Rev. Med. Virol. (2020) e02118.

[11] J. Favresse, C. Eucher, M. Elsen, K. Laffineur, J.M. Dogne, J. Douxfils, Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study, Clin. Chem. Lab. Med. (2020).

[12] J. Steiner, P.G. Kennedy, Acute disseminated encephalomyelitis: current knowledge and open questions, J. Neurovirol. 21 (2015) 473–479.

Arooshi Kumar\textsuperscript{a,b,c}, Anlys Olivera\textsuperscript{a,b}, Nancy Mueller\textsuperscript{b}, Jonathan Howard\textsuperscript{a,b}, Ariane Lewis\textsuperscript{b,c}

\textsuperscript{a} Department of Neurology, NYU Langone Medical Center, New York, NY 10016, United States of America

\textsuperscript{b} Department of Neurology, NYC Health + Hospitals/Bellevue, New York, NY 10016, United States of America

\textsuperscript{c} Department of Neurosurgery, NYU Langone Medical Center, New York, NY 10016, United States of America

E-mail address: arooshikumar@gmail.com (A. Kumar).

\textsuperscript{*} Corresponding author at: Department of Neurology, NYU Langone Medical Center, 530 First Avenue, HCC-5A, New York, NY 10016, USA.